IDEAS home Printed from
   My bibliography  Save this article

Estimating economic efficiency of preclinical diagnostics of Parkinson disease with cost-utility approach


  • Irina A. Denisova

    (Lomonosov Moscow State University, Moscow, Russia)

  • Tatiana V. Chubarova

    (Institute of Economics RAS, Moscow, Russia)

  • Irina E. Bogatova

    (Lomonosov Moscow State University, Moscow, Russia)

  • Sergei A. Vartanov

    (Lomonosov Moscow State University, Moscow, Russia)

  • Valerian G. Kucheryanu

    (Institute of General Pathology and Pathophysiology RAS, Moscow, Russia)

  • ViÑ tor M. Polterovich

    (Central Economics and Mathematics Institute RAS, Moscow, Russia
    Lomonosov Moscow State University, Moscow, Russia)

  • Natalia A. Turdyeva

    (Central Bank of the Russian Federation, Moscow, Russia)

  • Marina V. Shakleina

    (Lomonosov Moscow State University, Moscow, Russia)


Neurodegenerative diseases, Parkinson disease among them, set challenges to modern societies both in terms of premature deaths and resources spent on treatment of the diseases. At that, preventive care and early diagnostics in particular are potential directions towards higher economic efficiency of healthcare interventions in this area. Authors of this paper suggest a modification of the cost-utility approach to evaluate economic efficiency of an early diagnostics at the presymptomatic (prodromal) stage of Parkinson disease (PD), when its symptoms do not appear clinically yet. Such diagnostics, in combination with neuroprotective therapy for persons at high risk of PD, allows postponing its development until later years, and thereby ensuring an improvement in the quality of life of the population, as well as saving resources of the healthcare system and society as a whole. The authors rely on the diagnostic approach proposed by the research group headed by M. Ugryumov, which is currently at the stage of laboratory testing. Its implementation potentially leads to savings in both direct and indirect costs for PD treatment compared to the traditional approach, but increases testing costs, and also requires the development of new neuroprotective therapy for identified risk groups. The authors propose a modification of the cost-benefit assessment procedure to take into account the uncertainty associated with the lack of a final understanding of the scope and composition of the testing group at the preclinical stage. The condition for the economic efficiency of the preclinical diagnostic method in the developed procedure is the minimum permissible probability of detecting an increased risk of PD in the test group. To test their algorithm, the authors carry out calculations basing on the Russian data.

Suggested Citation

  • Irina A. Denisova & Tatiana V. Chubarova & Irina E. Bogatova & Sergei A. Vartanov & Valerian G. Kucheryanu & ViÑ tor M. Polterovich & Natalia A. Turdyeva & Marina V. Shakleina, 2020. "Estimating economic efficiency of preclinical diagnostics of Parkinson disease with cost-utility approach," Population and Economics, ARPHA Platform, vol. 4(3), pages 111-127, December.
  • Handle: RePEc:arh:jpopec:v:4:y:2020:i:3:p:111-127
    DOI: 10.3897/popecon.4.e59949

    Download full text from publisher

    File URL:
    Download Restriction: no

    File URL:
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item

    References listed on IDEAS

    1. Takeru Shiroiwa & Yoon‐Kyoung Sung & Takashi Fukuda & Hui‐Chu Lang & Sang‐Cheol Bae & Kiichiro Tsutani, 2010. "International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 422-437, April.
    Full references (including those not matched with items on IDEAS)


    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.

    Cited by:

    1. Tourdyeva, Natalia & Bogatova, Irina & Vartanov, Sergey & Denisova, Irina & Chubarova, Tatiana & Shakleina, Marina & Polterovich, Victor, 2021. "Расчетная Модель Общего Равновесия Для Оценки Экономического Эффекта Ранней Диагностики Болезни Паркинсона [Computable general equilibrium model for assessing the economic effect of early diagnosis," MPRA Paper 105182, University Library of Munich, Germany.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Fischer, Barbara & Telser, Harry & Zweifel, Peter & von Wyl, Viktor & Beck, Konstantin & Weber, Andreas, 2023. "The value of a QALY towards the end of life and its determinants: Experimental evidence," Social Science & Medicine, Elsevier, vol. 326(C).
    2. Ziebarth, Nicolas R. & Schmitt, Maike & Karlsson, Martin, 2013. "The Short-Term Population Health Effects of Weather and Pollution: Implications of Climate Change," IZA Discussion Papers 7875, Institute of Labor Economics (IZA).
    3. Maria Rubio-Valera & María Teresa Peñarrubia-María & Maria Iglesias-González & Martin Knapp & Paul McCrone & Marta Roig & Ramón Sabes-Figuera & Juan V. Luciano & Juan M. Mendive & Ana Gabriela Murruga, 2019. "Cost-effectiveness of antidepressants versus active monitoring for mild-to-moderate major depressive disorder: a multisite non-randomized-controlled trial in primary care (INFAP study)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 703-713, July.
    4. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
    5. Vincent T Janmaat & Marco J Bruno & Suzanne Polinder & Sylvie Lorenzen & Florian Lordick & Maikel P Peppelenbosch & Manon C W Spaander, 2016. "Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma," PLOS ONE, Public Library of Science, vol. 11(4), pages 1-10, April.
    6. Ava A John-Baptiste & Wei Wu & Paula Rochon & Geoffrey M Anderson & Chaim M Bell, 2013. "A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer," PLOS ONE, Public Library of Science, vol. 8(5), pages 1-9, May.
    7. Ryen, Linda & Svensson, Mikael, 2014. "The Willingness to Pay for a QALY: a Review of the Empirical Literature," Karlstad University Working Papers in Economics 12, Karlstad University, Department of Economics.
    8. Andrea Iannaccone & Thomas Marwick, 2015. "Cost Effectiveness of Transcatheter Aortic Valve Replacement Compared with Medical Management or Surgery for Patients with Aortic Stenosis," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 29-45, February.
    9. Penny Reeves & Kim Edmunds & Christopher Levi & Longting Lin & Xin Cheng & Richard Aviv & Tim Kleinig & Kenneth Butcher & Jingfen Zhang & Mark Parsons & Andrew Bivard, 2018. "Cost-effectiveness of targeted thrombolytic therapy for stroke patients using multi-modal CT compared to usual practice," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-11, October.
    10. Shiroiwa, Takeru & Fukuda, Takashi & Ikeda, Shunya & Takura, Tomoyuki, 2017. "New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations," Health Policy, Elsevier, vol. 121(8), pages 836-841.
    11. Claudia Schulz & Gisela Büchele & Raphael S. Peter & Dietrich Rothenbacher & Christian Brettschneider & Ulrich C. Liener & Clemens Becker & Kilian Rapp & Hans-Helmut König, 2021. "Health-economic evaluation of collaborative orthogeriatric care for patients with a hip fracture in Germany: a retrospective cohort study using health and long-term care insurance claims data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(6), pages 873-885, August.
    12. Shota Saito & Motoi Azumi & Yusuke Muneoka & Katsuhiko Nishino & Takashi Ishikawa & Yuichi Sato & Shuji Terai & Kouhei Akazawa, 2018. "Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 545-555, May.
    13. Jorge Barros-Garcia-Imhof & Andrés Jiménez-Alfonso & Inés Gómez-Acebo & María Fernández-Ortiz & Jéssica Alonso-Molero & Javier Llorca & Alejandro Gonzalez-Castro & Trinidad Dierssen-Sotos, 2022. "Perception of Medical Students on the Need for End-of-Life Care: A Q-Methodology Study," IJERPH, MDPI, vol. 19(13), pages 1-16, June.
    14. David Brain & Ruth Tulleners & Xing Lee & Qinglu Cheng & Nicholas Graves & Rosana Pacella, 2019. "Cost-effectiveness analysis of an innovative model of care for chronic wounds patients," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-13, March.
    15. Hoa‐Thi‐Minh Nguyen & Tom Kompas & Roslyn I. Hickson, 2014. "Aid and the Control of Tuberculosis in Papua New Guinea: Is Australia's Assistance Cost‐Effective?," Asia and the Pacific Policy Studies, Wiley Blackwell, vol. 1(2), pages 364-378, May.
    16. Andrew Gallagher & Violetta Shersher & Duncan Mortimer & Helen Truby & Terry Haines, 2023. "The Cost-Effectiveness of Adjunctive Lifestyle Interventions for the Management of Cancer: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 21(2), pages 225-242, March.
    17. Najme Moradi & Arash Rashidian & Shirin Nosratnejad & Alireza Olyaeemanesh & Marzieh Zanganeh & Leila Zarei, 2019. "The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method," PharmacoEconomics - Open, Springer, vol. 3(3), pages 311-319, September.
    18. Samuel Herzog & Marian Shanahan & Peter Grimison & Anh Tran & Nicole Wong & Nicholas Lintzeris & John Simes & Martin Stockler & Rachael L. Morton, 2018. "Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis," PharmacoEconomics, Springer, vol. 36(1), pages 67-78, January.
    19. Dastan Bamwesigye, 2023. "Willingness to Pay for Alternative Energies in Uganda: Energy Needs and Policy Instruments towards Zero Deforestation 2030 and Climate Change," Energies, MDPI, vol. 16(2), pages 1-21, January.
    20. Darryn Marks & Leanne Bisset & Tracy Comans & Michael Thomas & Shu Kay Ng & Shaun O’Leary & Philip G Conaghan & Paul A Scuffham, 2016. "Increasing Capacity for the Treatment of Common Musculoskeletal Problems: A Non-Inferiority RCT and Economic Analysis of Corticosteroid Injection for Shoulder Pain Comparing a Physiotherapist and Orth," PLOS ONE, Public Library of Science, vol. 11(9), pages 1-20, September.

    More about this item


    economic efficiency in healthcare; Parkinson disease; preclinical diagnostics; prodromal diagnostics; cost-utility approac;
    All these keywords.

    JEL classification:

    • H43 - Public Economics - - Publicly Provided Goods - - - Project Evaluation; Social Discount Rate
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:arh:jpopec:v:4:y:2020:i:3:p:111-127. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Teodor Georgiev (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.